S&P BSE 150 Midcap Index News and Updates

Name: Latest research reports of Bharat Dynamics Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Bharat Dynamics Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news on S&P BSE 150 Midcap Index from all sources in a single place.

Load latest

Bharat Dynamics Ltd.

13 Nov 2025

1512.70

-2.85%

Execution ramping up

Buy: Bharat Dynamics Ltd.

Recommendation Target

Motilal Oswal

Bharat Dynamics (BDL) delivered a strong performance in 2QFY26 as supply chain issues started easing out, resulting in a sharp execution ramp-up. However, margins were affected by project mix during the quarter.

Bharat Dynamics Ltd.'s price crossed below 30Day SMA today

Ashok Leyland Ltd.

13 Nov 2025

144.69

-1.06%

BP Equities Q2FY26 Result Update Ashok Leyland Ltd

Results Update: Ashok Leyland Ltd.

BP Wealth

...

Ashok Leyland Ltd. has gained 30.74% in the last 1 Year

Rail Vikas Nigam Ltd.

13 Nov 2025

314.00

-1.60%

Rail Vikas Nigam (RVNL): Q2FY26 Result Review

Hold: Rail Vikas Nigam Ltd.

Target

IDBI Capital

RVNL posted a disappointing Q2FY26, with weak profitability and cash flow offsetting modest revenue growth. Revenue from operations rose only 1% YoY to Rs49.3bn vs Rs48.7bn in Q2FY25 despite a healthy 26% QoQ rebound from the muted Rs39.2bn in Q1FY26. However, margins deteriorated sharply: EBITDA slipped to an estimated Rs3.9bn, translating to a 7.9% margin, down 120 bps YoY as cost pressures persisted and lower-margin EPC contracts formed a greater revenue share. PBT dropped 27% YoY to Rs3.bn, while PAT plunged 35% YoY to Rs1.9bn, with EPS falling to Rs0.94 vs Rs1.45 YoY. On the positive side,...

Rail Vikas Nigam Ltd. has an average target of 334.00 from 1 broker.

Ashok Leyland Ltd.

13 Nov 2025

144.69

-1.06%

Result Update:Ashok Leyland

Buy: Ashok Leyland Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock.

Ashok Leyland Ltd. is trading above all available SMAs

Fortis Healthcare Ltd.

13 Nov 2025

921.00

-1.54%

Result Update:Fortis Health.

Buy: Fortis Healthcare Ltd.

Target

Axis Direct

We maintain a BUY rating on Fortis Healthcare with a target price of Rs 1,070/share

Fortis Healthcare Ltd. is trading above its 200 day SMA of 803.5

PI Industries Ltd.

13 Nov 2025

3427.40

-0.40%

Result Update:P I Industries

Hold: PI Industries Ltd.

Target

Axis Direct

We maintain our HOLD rating on the stock.

Axis Direct decreased Hold price target of PI Industries Ltd. to 3800.0 on 13 Nov, 2025.

Biocon Ltd.

13 Nov 2025

396.85

0.43%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

we maintain a BUY rating on the stock.

Biocon Ltd. is trading above all available SMAs

Info Edge (India) Ltd.

13 Nov 2025

1340.40

-1.83%

Info Edge (India)

Buy: Info Edge (India) Ltd.

Target

ICICI Direct

About the stock: Info Edge (India) Ltd. (Info Edge), is a leading online classifieds company with a strong position in recruitment (naukri.com), real estate (99acres.com), matrimony (jeevansathi.com), and education (shiksha.com). Among its early investments in start-ups, Eternal (previously Zomato) with 12.43% stake...

Info Edge (India) Ltd. has an average target of 1530.25 from 5 brokers.

KPR Mill Ltd.

13 Nov 2025

1087.90

-0.62%

KPR Mills Ltd.

Buy: KPR Mill Ltd.

ICICI Direct

About the stock: KPR Mills (KPR), established in 1984, is one of the largest vertically integrated textile manufacturing companies in India. It has 6 spinning mills with a capacity of 1,00,000 MT of yarn and 4 garment facilities with capacity of 204 million knitted garments. The company also entered the sugar business with a sugar capacity of 20,000 TCD and ethanol capacity of 470KLPD p.a. Q2FY26 performance: KPR's consolidated revenues grew by 10.3%yoy to Rs1,632cr in Q2FY26. Textile business revenues grew by 4% YoY while sugar business revenues grew by 38% YoY (on base) during the quarter. Consolidated...

KPR Mill Ltd. is trading above all available SMAs

Lupin Ltd.

13 Nov 2025

2029.40

-0.07%

Record quarter with broad-based growth, strong U.S. momentum, and sharp margin expansion

Buy: Lupin Ltd.

Deven Choksey

Lupin remains well-positioned to sustain its strong growth trajectory, supported by a healthy specialty pipeline in the U.S., improved product mix, and operating leverage gains.

Deven Choksey released a Buy report for Lupin Ltd. with a price target of 2404.0 on 13 Nov, 2025.

S&P BSE 150 Midcap Index PB	5.2
S&P BSE 150 Midcap Index PE	34.5
S&P BSE 150 Midcap Index DIV	0.8
S&P BSE 150 Midcap Index EPS	480.2